
Phase 3 Trial Results With Amivantamab-vmjw Suggest Benefits for Patients With NSCLC, EGFR Mutations
Amivantamab-vmjw in combination with chemotherapy could assist patients diagnosed with non–small cell lung cancer when chemotherapy alone did not show benefit.





























